Biogen (BIIB) Equity Income (2012 - 2022)

Biogen has reported Equity Income for 8 years, with the latest figure at $3.4 million in Q3 2022.

• On a quarterly basis, Equity Income fell 93.28% year-over-year to $3.4 million in Q3 2022; TTM through Jun 2023 was $3.4 million, a 97.52% decrease from a year earlier, with the FY2022 full-year figure at $2.6 million, down 92.55% from the prior year.
• Equity Income was $3.4 million for Q3 2022 at Biogen, down from $45.0 million in the prior quarter.
• The five-year high for Equity Income was $50.6 million in Q3 2021, with the low at -$28.7 million in Q1 2019.
• Average Equity Income over 4 years is $12.3 million, with a median of $15.1 million recorded in 2020.
• The sharpest annual moves came in 2020 and 2022: Equity Income soared 255.05% in 2020, then slumped 93.28% in 2022.
• Over 4 years, Equity Income stood at $33.8 million in 2019, then slumped by 46.75% to $18.0 million in 2020, then surged by 150.0% to $45.0 million in 2021, then tumbled by 92.44% to $3.4 million in 2022.
• The last three Equity Income figures came in at $3.4 million (Q3 2022), $45.0 million (Q2 2022), and -$3.3 million (Q1 2022), per Business Quant data.